Trial Profile
A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Jan 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Antithymocyte globulin; Corticosteroids
- Indications Renal transplant rejection
- Focus Adverse reactions; Registrational
- 11 Jul 2008 New trial record.